YaoGeJu

← Back to list

Ixazomib Citrate Capsules

Matched
Active ingredients (original)
IXAZOMIB CITRATE
Dosage form (original)
CAPSULE
Route (original)
ORAL

Read these limits

  1. US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
  2. The Orange Book lists holder-submitted patents and does not cover all related patents.
  3. “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
  4. This page contains no sales or market-size data and cannot establish development value.
  5. Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.

US-approved products

Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.

Earliest approval2015/11/20
ANDA applications0
RLD applicantTAKEDA PHARMACEUTICALS USA INC

Currently marketed products: 3 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.

Application / product numberBrand name (original)Applicant (original)Dosage form (original)Route (original)Strength (original)Earliest approvalRLD / RSMarketing status (original)Official source
N208462-001NINLAROTAKEDA PHARMACEUTICALS USA INCCAPSULEORALIXAZOMIB CITRATE: EQ 2.3MG BASE2015/11/20Y / NHUMAN PRESCRIPTION DRUGopenFDA ↗
N208462-002NINLAROTAKEDA PHARMACEUTICALS USA INCCAPSULEORALIXAZOMIB CITRATE: EQ 3MG BASE2015/11/20Y / NHUMAN PRESCRIPTION DRUGopenFDA ↗
N208462-003NINLAROTAKEDA PHARMACEUTICALS USA INCCAPSULEORALIXAZOMIB CITRATE: EQ 4MG BASE2015/11/20Y / YHUMAN PRESCRIPTION DRUGopenFDA ↗

Listed US patents

*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.

Latest listed patent expiration2029/11/20
Substance patent expiration (DS flag)2029/11/20

This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.

Application / product numberPatent numberListed expirationSubstance / product flagsUse codeDelisting requestOfficial source
N208462-00174428302029/11/20Y / YU-2434—openFDA ↗
N208462-00176876622027/08/06Y / Y——openFDA ↗
N208462-00180038192027/08/06Y / YU-2434—openFDA ↗
N208462-00185306942027/08/06Y / YU-2434—openFDA ↗
N208462-00188595042029/06/16Y / Y——openFDA ↗
N208462-00188717452027/08/06— / —U-2434—openFDA ↗
N208462-00191750172029/06/16— / —U-2434—openFDA ↗
N208462-00274428302029/11/20Y / YU-2434—openFDA ↗
N208462-00276876622027/08/06Y / Y——openFDA ↗
N208462-00280038192027/08/06Y / YU-2434—openFDA ↗
N208462-00285306942027/08/06Y / YU-2434—openFDA ↗
N208462-00288595042029/06/16Y / Y——openFDA ↗
N208462-00288717452027/08/06— / —U-2434—openFDA ↗
N208462-00291750172029/06/16— / —U-2434—openFDA ↗
N208462-00374428302029/11/20Y / YU-2434—openFDA ↗
N208462-00376876622027/08/06Y / Y——openFDA ↗
N208462-00380038192027/08/06Y / YU-2434—openFDA ↗
N208462-00385306942027/08/06Y / YU-2434—openFDA ↗
N208462-00388595042029/06/16Y / Y——openFDA ↗
N208462-00388717452027/08/06— / —U-2434—openFDA ↗
N208462-00391750172029/06/16— / —U-2434—openFDA ↗

Exclusivity source records

FDA exclusivity code list ↗

Latest exclusivity expiration: —

Application / product numberExclusivity codeListed expirationOfficial source
Not listed

Chinese record details

Chinese product landscape ↗

The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Catalog holders 2

Company (original)Identifier (original)Source dateOfficial source
Qilu Pharmaceutical Co., Ltd.国药准字H20253310See source2025/01/24Official source ↗
Qilu Pharmaceutical Co., Ltd.国药准字H20253308See source2025/01/24Official source ↗
Qilu Pharmaceutical Co., Ltd.国药准字H20253309See source2025/01/24Official source ↗
Takeda Pharma A/SH201800122.3mg2018/04/12Official source ↗
Takeda Pharma A/SH201800113mg2018/04/12Official source ↗
Takeda Pharma A/SH201800104mg2018/04/12Official source ↗

NHSA approval numbers 3

Company (original)Identifier (original)Source dateOfficial source
Takeda Pharma A/S国药准字HJ20180012See source—Official source ↗
Takeda Pharma A/S国药准字HJ20180011See source—Official source ↗
Takeda Pharma A/S国药准字HJ20180010See source—Official source ↗

Under review 7

Company (original)Identifier (original)Source dateOfficial source
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024592026/10/09Official source ↗
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024582026/10/09Official source ↗
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024572026/10/09Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018832026/08/03Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018822026/08/03Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018812026/08/03Official source ↗
Huadong Medicine (Xi’an)Bodyguard Pharmaceutical Co.,Ltd.; Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd. romanizedCYHS25045262026/01/04Official source ↗

Generic-filing companies this year 3

Company (original)Identifier (original)Source dateOfficial source
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024592026/10/09Official source ↗
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024582026/10/09Official source ↗
Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized; Dong Yao Pharma Co., Ltd. romanizedCYHS26024572026/10/09Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018832026/08/03Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018822026/08/03Official source ↗
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTDCYHS26018812026/08/03Official source ↗
Huadong Medicine (Xi’an)Bodyguard Pharmaceutical Co.,Ltd.; Hangzhou Zhong Mei Hua Dong Pharmaceutical Co., Ltd. romanizedCYHS25045262026/01/04Official source ↗

API companies with A status 6

Company (original)Identifier (original)Source dateOfficial source
Sichuan Qing Mu Pharmaceutical Co., Ltd. romanizedY202500005492026/11/05Official source ↗
Sichuan Hui Yu Pharmaceutical Co., Ltd. romanizedY202500005342026/10/21Official source ↗
Jiangsu Tian Shi Li Di Yi Pharma Co., Ltd. romanizedY202500001032026/06/30Official source ↗
Shandong Xin Shi Dai Pharma Co., Ltd. romanizedY202400014752026/07/21Official source ↗
Qilu Pharmaceutical Co., Ltd.Y202300007212026/05/22Official source ↗
Sichuan Kelun Pharmaceutical Co., Ltd.Y202300001102024/11/21Official source ↗

Trial registrations 2025/2026 —

Not loaded

Sources and dates

FDA Orange Book
2026/11/06
CDE acceptance and review
2026/11/13 06:42
Chemical Drug Catalog
2026/11/13 06:39
API registration records
2026/11/13 06:41
NHSA drug code database
2026/10/23
Trial registry
2026/11/13 08:09 · Incomplete coverage

Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.

Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗

Name and dosage-form matching sources